Lancet Respir Med:注意!加用环磷酰胺对特发性肺纤维化急性加重患者而言有害无利!

2021-09-10 Nebula MedSci原创

在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率

环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。本研究旨在评估除了高剂量甲泼尼龙之外的四种环磷酰胺冲击在 IPF 急性加重患者中的有效性和安全性。

这是一项在法国的 31 家医院开展的双盲、安慰剂为对照的 3 期临床试验,招募了年满 18 岁的 IPF 急性加重或疑似加重患者,1:1随机分成两组,于第0/15/30/60天时接受环磷酰胺(600 mg/m2)静脉冲击+尿嘧啶或安慰剂作为出血性膀胱炎的预防治疗,4 小时后重复用药。排除接受机械通气、有活动性感染、有活动性癌症或在肺移植等候名单上登记的患者。主要终点是 3 个月全因死亡率。

主要终点

2016年1月22日-2018年7月19日,共评估了 183 位患者,其中 120 位被随机分组,119 位(62 位为重度 IPF)接受了至少一剂量的环磷酰胺(n=60)或安慰剂(n=59)。环磷酰胺组和安慰剂组的 3 个月全因死亡率分别是 45%(27/60)和31%(18/59;差值 14.5%,p=0.10)。根据 IPF 严重程度调整后的结果相似(优势比[OR] 1.89, 95%CI 0.89-4.04)。重度 IPF 患者的3 个月死亡风险高于非重度 IPF 患者(OR 2.62, 1.12-6.12),抗纤维化治疗与 3 个月死亡风险降低相关(OR 0.33, 0.13-0.82)。

12个月存活率

两组 6 个月内的不良事件的发生情况相近:环磷酰胺组 vs 安慰剂组:42% vs 51%;最常见的是感染:33% vs 36%。

不良事件

综上所述,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率。该研究结果提供了反对在此类患者中使用静脉输注环磷酰胺的证据。

原始出处:

Jean-Marc Naccache, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. September 07, 2021. https://doi.org/10.1016/S2213-2600(21)00354-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2022-01-16 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-11 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-10 1453df99m58暂无昵称

    环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1831295, encodeId=ba4e183129597, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jan 16 01:09:50 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894819, encodeId=36dd189481958, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Jun 03 00:09:50 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894418, encodeId=a9431894418d2, content=<a href='/topic/show?id=db705221569' target=_blank style='color:#2F92EE;'>#急性加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52215, encryptionId=db705221569, topicName=急性加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Mon Feb 07 02:09:50 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284378, encodeId=5e8312843e8ab, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611246, encodeId=af3a1611246aa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 12 12:09:50 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034448, encodeId=672f10344484c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Sep 11 00:09:50 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016428, encodeId=02e31016428e4, content=环磷酰胺在特发性肺纤维化 (IPF) 急性加重患者中的应用尚不明确。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Fri Sep 10 23:05:00 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016407, encodeId=23e6101640e29, content=,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Sep 10 21:39:58 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-10 易水河

    ,在糖皮质激素治疗基础上,额外加用环磷酰胺冲击治疗会增加特发性肺纤维急性加重患者的 3 个月死亡率 。

    0

相关资讯

Radiology:三维UTE MRI序列在囊性肺纤维化肺功能成像中的应用

肺囊性纤维化(CF)是在白人人群中发现的最常见的常染色体隐性遗传疾病之一,对肺部的进行性感染是该病发病率和死亡率的主要原因。

Radiology:CT随访发现重度COVID-19幸存者肺间质异常持续存在

重度COVID-19幸存者在6个月CT扫描中显示的纤维化间质肺异常在1年CT扫描中持续存在,并与肺扩散能力呈负相关。

JCEM:糖尿病与特发性肺纤维化之间的关联

与非IPF对照者相比,IPF患者患DM的几率增加了1.54倍,而DM患者患IPF的风险是否增加仍存在争议。因此,很有必要进一步开展大型前瞻性队列研究来调查DM患者IPF的患病率。

Cell Death Differ:lncRNA PFI调控SRSF1的表达及活性以预防肺纤维化的发生

肺纤维化(PF)是一种进行性的、不可逆转的、病因复杂、死亡率高的慢性炎症性疾病,其与年龄密切相关且治疗选择有限。

综述:特发性肺纤维化治疗药物治疗进展

特发性肺纤维化( IPF ),是特发性间质性肺炎中最常见和最严重的疾病,是一种未知原因的慢性疾病,其特征是肺实质进行性瘢痕形成,最终导致肺功能丧失,死于呼吸衰竭,IPF的中位生存期大约为2-3年。IP

Biomed Pharmacother:中医药联合肺部给药系统防治特发性肺纤维化可行性探讨

特发性肺纤维化 (IPF) 是一种病因不明的进行性肺间质炎性疾病,也是冠状病毒病重症患者的后遗症。中医药作为一种独特的医学疗法,通过多层次、多靶点的方法,在全球范围内逐渐发挥其在IPF治疗中的优势。